Review Article

Looking for Pyroptosis-Modulating miRNAs as a Therapeutic Target for Improving Myocardium Survival

Seahyoung Lee,¹,² Eunhyun Choi,¹,² Min-Ji Cha,¹,² and Ki-Chul Hwang¹,²

¹Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do 210-701, Republic of Korea
²Catholic Kwandong University International St. Mary’s Hospital, Incheon Metropolitan City 404-834, Republic of Korea

Correspondence should be addressed to Ki-Chul Hwang; kchwang@cku.ac.kr

Received 11 November 2014; Accepted 15 January 2015

1. Introduction

Heart disease has been the leading cause of death worldwide for many decades [1], and the loss of cells in the myocardium mutually affects the development of various heart diseases with functional demise of myocardium that can ultimately result in heart failure. In a dire situation such as ischemia, where nutrients and oxygen are deprived, individual cells are subjected to a live or die decision, and various cell death mechanisms can be activated as results [2, 3]. Among different cell death mechanisms, pyroptosis is the most recently recognized form of programmed cell death. Pyroptosis, first discovered by Cookson and Brennan in 2001, is characterized by cell lysis and inflammatory cytokine release [4]. Pyroptosis differs from apoptosis in that it does not show the typical membrane blebbing of apoptosis while inducing cell lysis, swelling, and pore formation that are not observed in apoptosis. Furthermore, the type of cysteine-dependent aspartate-specific proteases (caspases) that orchestrates disassembly of the cells in pyroptosis is caspase-1 as opposed to the caspase-3 of apoptosis [2]. In an evolutionary point of view, it is believed that pyroptosis initially developed as a host defense against microbial infections [5]. However, pyroptosis can be induced under noninfectious conditions. For example, typical signs of pyroptosis such as upregulation of caspase-1 and interleukin 1β (IL-1β) in myocardial infarction (MI) have been reported [6], suggesting that modulation of pyroptosis may be a viable therapeutic target for alleviating selective cardiovascular diseases such as MI.

During the last decade, a new class of small, noncoding RNAs termed microRNAs (miRNAs) has emerged as a key regulator of cellular process such as survival, differentiation, and death [7, 8]. Naturally, it is not too far-fetched of an assumption that the development of pyroptosis is also regulated by miRNAs to some extent, and we aim to summarize currently known pyroptosis-modulating miRNAs and others might be involved in pyroptosis based on its expressions in physiologic/pathologic hearts and the analysis of predicted targets. Through this mini review, we aim to provide a glimpse of how miRNA-dependent regulation of pyroptosis fits into a bigger picture of physiologic and pathologic regulation of heart cells by examining any possible connections of those miRNAs to other cardiovascular diseases (CVDs). Furthermore, we hope to offer constructive suggestions for...
conducting future studies investigating the role of miRNAs in pyroptosis and their potential as a therapeutic target for preventing undesired loss of the heart cells in CVDs.

2. MicroRNAs at a Glance

MicroRNAs are relatively short (approximately 21–23 nucleotides long), noncoding RNAs that bind to target mRNAs with complementary sequences for degradation and/or translation repression of the target mRNAs, thus acting as a posttranscriptional regulator of genes [9]. Initially, miRNA is transcribed as usually thousands of nucleotide long, primary transcript called pri-miRNA by RNA polymerase II in the nucleus. This pri-miRNA is subsequently processed by the ribonuclease III Drosha to produce approximately hundred nucleotides long premature miRNA (pre-miRNA) with hairpin-like structure. After being transferred to the cytosol by the nuclear export factor Exportin 5, pre-miRNA is further processed by ribonuclease III Dicer to produce a mature miRNA [10]. The double stranded mature miRNA has a short-life so it promptly unwound into two strands and more stable strand associates with argonaute (Ago) protein, which comprises a RNA-induced silencing complex (RISC) [11]. The RISC utilizes miRNA as a template to recognize the complementary sequence in the 3’ untranslated region (UTR) of target mRNA [12]. As a result, gene silencing is achieved via either hindered mRNA translation or mRNA degradation [13]. Since their first discovery in 1993 [14], miRNAs have been implicated in various diseases including CVDs [15–17]. Pertaining to cardiomyocyte death, the importance of miRNA-mediated regulations in cardiac apoptosis [18,19] and autophagy [20,21] has been reported.

3. Pyroptosis

Meaning “fire + falling” in Greek, pyroptosis is a proinflammatory cellular suicide program and part of the host defense system responding to pathogens. Initial step of pyroptosis is the formation of caspase-1 binding protein complexes called inflammasome, and this is triggered by the cytosolic receptor-mediated recognition of bacterial and/or viral pathogens or host danger signals such as pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs) [2,22].

3.1. Inflammasome. Inflammasome generally consisted of a cytosolic pattern-recognition receptor (PRR), caspase-1, and an adaptor protein that connects caspase-1 to the cytosolic PRR [22].

3.1.1. Cytosolic PRRs. The cytosolic PRRs function as cytosolic molecular sensors and they are either NOD-like receptor (NLR) family proteins or pyrin and HIN domain-containing (PYHIN) proteins [23]. In humans, the NLRs family consists of 22 members and has 3 distinctive subfamilies: the NODs (NOD1-2, NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX1, and CIITA), the NLRPs (NLRP1-14, also known as NALPs), and IPAF (NLRC4 and NAIP) [24]. Each NLR contains three distinct domains, namely, an N-terminal effector domain, a central nucleotide binding and oligomerization (NACHT) domain, and a C-terminal leucine-rich repeat (LRR) domain. The N-terminal effector domain facilitates signal transduction and four different types have been identified: acidic transactivation domain, caspase activation and recruitment domain (CARD), pyrin domain (PYD), and baculoviral inhibitor of apoptosis protein (IAP) repeat domain. The NACHT domain facilitates signaling complex activation via ATP-dependent oligomerization, and the C-terminal LRR domain is responsible for ligand sensing and autoinhibition [25].

3.1.2. Caspase-1 and Adaptor Protein. Formerly known as interleukin 1β converting enzyme (ICE), caspase-1 was the first caspase identified in mammals [26]. In humans, caspase-1, caspase-4, caspase-5, and caspase-12 comprise inflammatory caspases [27] as opposed to apoptotic caspases such as caspase-3, and, as a member the inflammatory caspases, caspase-1 does not contribute to apoptosis. In relation to CVDs, caspase-1-mediated cardiomyocyte death has been reported [28]. Like caspase-9 which is activated via formation of apoptosome with apoptotic protease-activating factor-1 (Apaf-1) during apoptosis [29], caspase-1 is activated through interaction with inflammasome during the process of pyroptosis. At resting state, NLR monomers stay in inactive conformation. Upon activation, NLR monomers oligomerize via homotypic interaction of NACHT domains and bind to the adapter protein called apoptosis-associated speck-like protein containing a CARD (ASC/PYCARD) through PYD-PYD interaction [30]. Subsequently, these adaptor proteins recruit procaspase-1 via homotypic CARD interaction and cleave to activate the recruited procaspase-1 by induced proximity mechanism [31,32]. The major mechanism of activated caspase-1-mediated pyroptosis is the formation of ion-permeable pores in the plasma membrane which creates osmotic pressure driving water influx, subsequent cell swelling, and eventual cell lysis with the release of intracellular content [33]. These released cytoplasmic contents become DAMPs and trigger further pyroptotic cascade [34]. Additionally, the activated caspase-1 mediates maturation of IL-1β and -18 inducing inflammatory responses [35]. Although this caspase-1-mediated inflammatory response was proven not to be indispensable for cell death [36], the significant role of both IL-1β and -18 in the development and progression of CVDs has been reported [37–39].

4. Approaches to Finding Candidate Pyroptosis-Modulating miRNAs

Currently, only few miRNAs have been identified as meaningful mediators of pyroptosis. However, this insufficient empirical data on the miRNA-dependent regulation of pyroptosis does not necessarily indicate that the role of miRNAs in the development and progression of pyroptosis is insignificant. Rather, it is probably due to the fact that this field of miRNA-mediated regulation of pyroptosis is in its infancy and the number of studies on this subject is anticipated to increase.
in upcoming years. Thus, in this section, we try to offer some feasible research strategies for future studies focusing on how to systematically downsize the number of candidate miRNAs suspected to be involved in the development and progression of pyroptosis. Additionally, currently available information of the miRNA-dependent regulation of pyroptosis will be discussed where appropriate.

4.1. Scenario 1: miRNAs Directly Targeting Key Mediators of Pyroptosis. This is the most intuitive and straightforward case, and the most reasonable approach will be finding miRNAs directly targeting key protein-based mediators of pyroptosis such as pattern recognition receptors (NOD-like receptor (NLR) family of proteins), adaptor proteins, and caspase-1 based on miRNA databases such as, but not limited to, TargetScan [40] and miRWalk [41]. In this case, the first task to be done is to list up possible targets, along with a list of miRNAs (referred to as predicted miRNAs) predicted to target each of the specific proteins of interest (i.e., individual NLR proteins). Next, miRNAs that are dysregulated (referred to as dysregulated miRNAs) in CVDs have to be summarized from individual research articles or review articles providing miRNAs profile in CVDs. Of note, in this particular scenario, “dysregulated” especially means “decreased” because miRNAs are generally a negative regulator of target genes. For example, recent studies have reported that miR-223 directly targets NLRP3 acting as a negative regulator of inflammasome formation [42, 43]. Those were two of the few studies that addressed the evidence of miRNA-dependent regulation of pyroptosis. In this particular case, if miR-223 were to be a link between pyropothesis and CVDs, the expression level of miR-223 would be decreased in CVDs of interests so that the expression of NLRP3 can be increased suppressing inflammasome formation. Nevertheless, we could only identify that one study reported decrease of miR-223 in CVDs [44], and further association between the downregulation of miR-223 and CVDs could not be found. Now, back to the bioinformatic screening process, by crosschecking the dysregulated miRNAs and the predicted miRNAs, one can logically conduct a rough screening of miRNAs for possible involvement in both pyroptosis and CVDs, as exemplified in Table 1.

For example, miR-1 has been reported to be downregulated in various CVDs including myocardial infarction (MI) [45–47], and it is predicted to target multiple NLR proteins (NOD1, NLRP14, and NAIP). Since it has been also documented that acute MI increased caspase-1 activity and formation of inflammasome [48], decreased miR-1 during MI might be an unappreciated pyroptosis suppressor by which the synthesis of inflammasome components is enhanced contributing to the development of pyroptosis. Nevertheless, such deductive reasoning should be empirically tested and validated. In such cases, exogenous delivery of corresponding miRNA mimics or finding ways to increase and/or maintain the endogenous level (i.e., small-molecules increasing specific miRNAs) would be appropriate.

4.2. Scenario 2: miRNAs Indirectly Affect Pyroptosis via Secondary Mediators. In this case, the premise is that miRNAs target regulators of pyroptosis (as opposed to components of inflammasome). This case can be further divided into two possible scenarios: miRNAs target negative regulators or miRNAs target positive regulators. Depending on the type of regulators, the expression patterns of miRNAs in CVDs to look for can be either downregulation or upregulation (Table 2).

Since the same strategy used for the scenario 1 can be applied for the case of miRNAs targeting positive regulators, only the case of miRNAs targeting negative regulators of pyroptosis will be covered in this section. A good example would be the NLRP3 inflammasome. The NLRP3 inflammasome has been recently reported to be involved in ischemia-reperfusion- (I/R-) induced myocardial injury [6], and number of negative regulators have been identified [49]. As laid out above, miRNAs targeting negative regulators should be increased in CVDs to facilitate enhanced pyroptosis. Selected examples of negative regulators and miRNAs targeting those regulators are summarized in Table 3.

4.2.1. Autophagy-Mediated Suppression of Inflammasome Activation. Meaning “self-eating” in Greek, autophagy is a highly conserved process by which long-lived proteins and/or organelles are delivered to the lysosome and degraded within [50]. Negative regulation of pyroptosis by autophagy was demonstrated by the previous study reporting that knockout of Atg16L1 (autophagy-related gene 16-like 1), one of the key factors of autophagy [51], significantly enhanced inflammasome activation and caspase-1 activation [52]. Additional key components of autophagy, namely, LC3B and beclin1 [53], also have been reported to function as negative regulators of pyroptosis by inhibiting activation of inflammasomes [54]. These data indicate that if miRNAs targeting those autophagic proteins are upregulated during certain CVDs, those miRNAs can negate the negative regulation of pyroptosis by autophagic process resulting in enhanced pyroptosis.

4.2.2. Transcription Factors Negatively Regulating Inflammasome Activation. Examples of transcription factors acting as a negative regulator of pyroptosis are signal transducers and activators of transcription 1 (STAT1) and forkhead box O3 (FOXO3a). Activated as a downstream signal of type I interferon (IFN) [55], STAT1 repressed the activity of NLRP1 and 3 inflammasomes subsequently hindering pyroptosis [56]. Consequently, miRNAs targeting STAT1 can act as a positive inducer of pyroptosis, and if such miRNAs are upregulated in CVDs, their potential as a linker between CVDs and pyroptosis will be worth examining. Another transcription factor that has been reported to be involved in negative regulation of pyroptosis is FOXO3a [57]. In that particular study, miR-30d increased downregulating one of its targets, FOXO3a, under a high-glucose condition. As a result, the apoptosis repressor with caspase recruitment domain (ARC) that is under the transcriptional regulation of FOXO3a [58] was decreased so that caspase-1 was upregulated and pyroptosis was induced. This was the last study providing the evidence of miRNA-dependent regulation of pyroptosis and is an excellent empirical example of scenario 2 where...
Table 1: Examples of miRNA downregulated in CVDs with potential connection on pyroptosis.

| Human inflammasome component (NCBI RefSeq) | miRNAs predicted by *TargetScan and reported to be downregulated in CVDs | Related CVDs [reference] |
|-------------------------------------------|-------------------------------------------------------------------------|---------------------------|
| NLR proteins (NODs)                      |                                                                         |                           |
| NOD1 (NM_006092)                         | miR-1, miR-133, miR-208, miR-499, miR-30e-5p                           | DCM, AS [45], MI [46], LVH [47] |
| NOD2 (NM_022162)                         | miR-208, miR-499                                                       | AS [45], MI [46]          |
| NOD3/NLRC3 (NM_178844)                   | miR-24, miR-499                                                        | MI [59, 60]               |
| NOD4/NLRC5 (NM_032206)                   | miR-24, miR-499                                                        | MI [59, 60]               |
| NOD5/NLRCX1 (NM_024618)                  | miR-10, miR-24, miR-133                                               | AS [45], MI [46]          |
| CIITA (NM_000246)                        | miR-10, miR-24                                                        | AS [45], MI [46]          |
| NLR proteins (NOD-like receptor family pyrin domain containing, LNRPs) |                                                                         |                           |
| NLRP1 (NM_014922)                        | miR-10, miR-17-5p, miR-30e-5p                                          | AS [45], DCM [45], AS [45] |
| NLRP2 (NM_017852)                        |                                                                         | DCM [45]                  |
| NLRP3 (NM_004895)                        |                                                                         | DCM [45]                  |
| NLRP4 (NM_134444)                        |                                                                         | DCM [45]                  |
| NLRP5 (NM_153447)                        |                                                                         | DCM [45]                  |
| NLRP6                                     |                                                                         | DCM [45]                  |
| NLRP7 (NM_139176)                        | miR-150, miR-155, miR-19                                               | MI [62], LVH [63]         |
| NLRP8 (NM_176811)                        |                                                                         | DCM, AS [45]              |
| NLRP9 (NM_176820)                        |                                                                         | Prediction data not available |
| NLRP10                                    |                                                                         | Prediction data not available |
| NLRP11 (NM_145007)                       |                                                                         | Prediction data not available |
| NLRP12 (NM_033297)                       |                                                                         | Prediction data not available |
| NLRP13                                    |                                                                         | Prediction data not available |
| NLRP14 (NM_176822)                       | miR-1, miR-150                                                         | DCM, AS [45], MI [46], LVH [47] |

NLR proteins (ice protease-activating factor (IPAF))

| NLRC4 (NM_021209)                        |                                                                         | No miRNA meets the screening criteria |
| NAIIP (NM_004536)                        |                                                                         | No miRNA meets the screening criteria |
| Caspase                                   |                                                                         | No miRNA meets the screening criteria |
| Caspase-1 (NM_001223)                    |                                                                         | No miRNA meets the screening criteria |
| Adaptor protein                          |                                                                         | No miRNA meets the screening criteria |

*In TargetScan search, only the “miRNA families broadly conserved among vertebrates” for each of the target proteins were used to generate this table. DCM: dilated cardiomyopathy, AS: aortic stenosis, MI: myocardial infarction, and LVH: left ventricular hypertrophy.
Table 2: Screening criteria of miRNAs, dependent on pyroptosis regulator type.

| Type of regulators            | Corresponding miRNA expressions in CVDs                                      |
|-------------------------------|--------------------------------------------------------------------------------|
| Positive regulators (promote pyroptosis) | Decreased, abundant positive regulators expected                               |
| Negative regulators (inhibit pyroptosis) | Increased, depletion of negative regulators expected                           |

Table 3: Selected examples of miRNAs targeting human negative regulators of pyroptosis and reported to be increased in CVDs.

| Negative regulators of pyroptosis (NCBI Refseq, reference) | miRNAs predicted by *TargetScan and reported to be upregulated in CVDs | Related CVDs [reference] |
|----------------------------------------------------------|---------------------------------------------------------------------|-------------------------|
| Autophagy                                                |                                                                     |                         |
| ATG16L1 (autophagy-related gene 16 like-1) (NM_017974, [52]) | Let-7                                                               | DCM, ICM, AS [45]       |
|                                                          | miR-125                                                             | DCM [45, 64], AS [45], LVH [65] |
|                                                          | miR-181                                                             | DCM [64], AS [45]       |
|                                                          | miR-214                                                             | DCM [45, 64], ICM, AS [45], LVH [65] |
|                                                          | miR-30e-5p                                                          | DCM, AS [45]            |
| MAP1LC3B (microtubule-associated proteins 1A/1B light chain 3B) (NM_022818, [54]) | miR-145                                                            | AS [45]                 |
|                                                          | miR-214                                                             | DCM, ICM, AS [45], LVH [65, 66] |
|                                                          | miR-221                                                             | LVH [65]                |
|                                                          | miR-222                                                             | DCM, ICM [45], LVH [65] |
|                                                          | miR-30e-5p                                                          | DCM, AS [45]            |
| BECN1 (Beclin1) (NM_003766, [54])                      |                                                                     |                         |
|                                                          | miR-199                                                             | DCM, ICM [45], LVH [65, 66] |
| Transcription factors                                    |                                                                     |                         |
| STAT1 (NM_007315, [56])                                  |                                                                     |                         |
|                                                          | miR-140                                                             | DCM, ICM, AS [45], LVH [65] |
|                                                          | miR-21                                                              | LVH [65, 66]            |
|                                                          | miR-23                                                              | DCM, ICM, AS [45], LVH [65, 66] |
|                                                          | miR-24                                                              | ICM, AS [45]            |
|                                                          | miR-27                                                              | LVH [65, 66]            |
| FOXO3 (NM_001455)                                        | *experimentally proven to be regulated by miR-30d [57]               | Diabetic cardiomyopathy [57] |
|                                                          | miR-30d                                                             | DCM, AS [45]            |
|                                                          | miR-99                                                              | DCM, ICM, AS [45], LVH [65] |
|                                                          | miR-103                                                             | DCM, AS [45], LVH [65, 66] |
|                                                          | miR-125                                                             | LVH [66]                |
|                                                          | miR-217                                                             | LVH [65]                |
|                                                          | miR-221/222                                                         |                         |
| NO synthase                                              |                                                                     |                         |
| NOS2 (inducible nitric oxide synthase) (NM_000625, [67]) |                                                                     |                         |
|                                                          | miR-15                                                              | DCM, AS [45]            |
|                                                          | miR-214                                                             | DCM [64], LVH [65, 66]  |

*In TargetScan search, only the “miRNA families broadly conserved among vertebrates” for each of the target proteins were used to generate this table. DCM: dilated cardiomyopathy, AS: aortic stenosis, MI: myocardial infarction, and LVH: left ventricular hypertrophy.

miRNAs (i.e., miR-30d) increased in CVDs (i.e., diabetic cardiomyopathy) and such increase caused downregulation of negative regulator of pyroptosis (i.e., ARC transcribed by FOXO3a).

4.2.3. Nitric Oxide-Mediated Suppression of Inflammasome Formation. Nitric oxide (NO) has been reported to negatively regulate NLRP3 inflammasome-mediated caspase-1 activation [67]. Such results indicated that inducible nitric oxide synthase (iNOS), which is responsible for the production of NO [68], also can be a negative regulator of NLRP3 inflammasome. In fact, the significance of iNOS has been demonstrated in a study where IFN-β inhibited NLRP3 inflammasome [69]. Furthermore, since NO itself is not a protein that can be subjected to miRNA-dependent targeting, finding miRNAs that are increased in CVDs, as well as targeting iNOS, would be the next logical strategy for designing studies to elucidate the role of miRNAs in myocardial pyroptosis.

5. Concluding Remarks

Over the last few decades, tremendous interest has been placed on the regulatory nature of miRNAs under various pathologic conditions including CVDs. Considering the complexity of cell signaling in general, it is reasonable to...
assume that miRNAs are involved in virtually all biological processes including demise of cells. In this mini review, we tried to provide currently available evidences of miRNA-dependent regulation of pyroptosis. However, due to the limited number of studies, it was not sufficient to draw any significant insights on the role of miRNAs in pyroptosis, and it remains as one of the limitations of this review.

In addition to providing the evidences of miRNA-dependent modulation of pyroptosis, we also tried to offer some suggestions for future studies focusing on what to look for in search of the miRNAs modulating pyroptosis in CVDs. The aim of this review was to encourage scientific interest in examining the need-to-be-further-validated framework for in search of the miRNAs modulating pyroptosis in CVDs. We hope that, through future studies with well-thought-out strategies, our understanding of the subject of miRNA-dependent regulation of pyroptosis in CVDs is enhanced, and it contributes to the development of an optimized miRNA-mediated therapeutic strategy for targeting cell death of myocardium.

Conflict of Interests
The authors declare no conflict of interests.

Authors’ Contribution
Seahyoung Lee and Eunhyun Choi equally contributed to this work.

Acknowledgments
This study was supported by a Korea Science and Engineering Foundation grant funded by the Korean government (MEST) (2014030459) and a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A120478).

References
[1] C. Mathers, D. M. Fat, J. T. Boerma, and World Health Organization, The Global Burden of Disease: 2004 Update, World Health Organization, Geneva, Switzerland, 2008.
[2] L. Duprez, E. Wirawan, T. V. Berghe, and P. Vandenabeele, “Major cell death pathways at a glance,” Microbes and Infection, vol. 11, no. 13, pp. 1050–1062, 2009.
[3] M. Chiong, Z. V. Wang, Z. Pedrozo et al., “Cardiomyocyte death: mechanisms and translational implications,” Cell Death and Disease, vol. 2, article e244, 2011.
[4] B. T. Cookson and M. A. Brennan, “Pro-inflammatory programmed cell death,” Trends in Microbiology, vol. 9, no. 3, pp. 113–114, 2001.
[5] M. Dagenais, A. Skeldon, and M. Saleh, “The inflammasome: in memory of Dr. Jurg Tschopp,” Cell Death and Differentiation, vol. 19, no. 1, pp. 5–12, 2012.
[6] Ø. Sandanger, T. Ranheim, L. E. Vinge et al., “The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury,” Cardiovascular Research, vol. 99, no. 1, pp. 164–174, 2013.
[7] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[8] Z. Wang, “MicroRNA: a matter of life or death,” World Journal of Biological Chemistry, vol. 1, no. 4, pp. 41–54, 2010.
[9] C. Sevignani, G. A. Calin, L. D. Siracusa, and C. M. Croce, “Mammalian microRNAs: a small world for fine-tuning gene expression,” Mammalian Genome, vol. 17, no. 3, pp. 189–202, 2006.
[10] M. Ha and V. N. Kim, “Regulation of microRNA biogenesis,” Nature Reviews Molecular Cell Biology, vol. 15, no. 8, pp. 509–524, 2014.
[11] V. N. Kim, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376–385, 2005.
[12] Y. Kim and V. N. Kim, “MicroRNA factory: RISC assembly from precursor microRNAs,” Molecular Cell, vol. 46, no. 4, pp. 384–386, 2012.
[13] M. R. Fabian and N. Sonenberg, “The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC,” Nature Structural & Molecular Biology, vol. 19, no. 6, pp. 586–593, 2012.
[14] R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993.
[15] A. M. Ardekani and M. M. Naeini, “The role of microRNAs in human diseases,” Avicenna Journal of Medical Biotechnology, vol. 2, no. 4, pp. 161–179, 2010.
[16] E. M. Small, R. J. A. Frost, and E. N. Olson, “MicroRNAs add a new dimension to cardiovascular disease,” Circulation, vol. 121, no. 8, pp. 1022–1032, 2010.
[17] G. Condorelli, M. V. G. Latromento, and E. Cavarretta, “MicroRNAs in cardiovascular diseases: current knowledge and the road ahead,” Journal of the American College of Cardiology, vol. 63, no. 21, pp. 2177–2187, 2014.
[18] W. Du, Z. Pan, X. Chen et al., “By targeting stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion,” Cellular Physiology and Biochemistry, vol. 34, no. 3, pp. 955–965, 2014.
[19] C. Xu, Y. Hu, L. Hou et al., “β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression,” Journal of Molecular and Cellular Cardiology, vol. 75, pp. 111–121, 2014.
[20] Q. Li, J. Xie, R. Li et al., “Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction,” Journal of Cellular and Molecular Medicine, vol. 18, no. 5, pp. 919–928, 2014.
[21] J. Huang, W. Sun, H. Huang et al., “MiR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A Expression and Autophagic Activity,” PLoS ONE, vol. 9, no. 4, Article ID e94382, 2014.
[22] E. Latz, T. S. Xiao, and A. Stutz, “Activation and regulation of the inflammasomes,” Nature Reviews Immunology, vol. 13, no. 6, pp. 397–411, 2013.
[23] J. G. Walsh, D. A. Muruve, and C. Power, “Inflammasomes in the CNS,” Nature Reviews Neuroscience, vol. 15, no. 2, pp. 84–97, 2014.
[24] K. Schroder and J. Tschopp, “The Inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010.
[25] M. Proell, S. J. Riedl, J. H. Fritz, A. M. Rojas, and R. Schwarzenbacher, “The Nod-like Receptor (NLR) family: a tale of similarities and differences,” PLoS ONE, vol. 3, no. 4, Article ID e2119, 2008.
[26] N. A. Thornberry, H. G. Bull, J. R. Calaycay et al., “A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes,” Nature, vol. 356, no. 6372, pp. 768–774, 1992.

[27] D. R. Mcllwain, T. Berger, and T. W. Mak, “Caspase functions in cell death and disease,” Cold Spring Harbor perspectives in biology, vol. 5, no. 4, 2013.

[28] S. Merkle, S. Frantz, M. P. Schön et al., “A role for caspase-1 in heart failure,” Circulation Research, vol. 100, no. 5, pp. 645–653, 2007.

[29] S. B. Bratton and G. S. Salvesen, “Regulation of the Apaf-1-caspase-9 apoptosome,” Journal of Cell Science, vol. 123, part 19, pp. 3209–3214, 2010.

[30] J. P.-Y. Ting, S. B. Willingham, and D. T. Bergstralh, “NLRs at the intersection of cell death and immunity,” Nature Reviews Immunology, vol. 8, no. 5, pp. 372–379, 2008.

[31] S. M. Srinivasula, J.-L. Poyet, M. Razmara, P. Datta, Z. Zhang, and E. S. Alnemri, “The PYRIN-CARD protein ASC is an activating adaptor for caspase-1,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21119–21122, 2002.

[32] B. K. Davis, H. Wen, and J. P.-Y. Ting, “The Inflammasome NLRs in immunity, inflammation, and associated diseases,” Annual Review of Immunology, vol. 29, pp. 707–735, 2011.

[33] S. L. Fink and B. T. Cookson, “Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages,” Cellular Microbiology, vol. 8, no. II, pp. 1812–1825, 2006.

[34] K. Newton and V. M. Dixit, “Signaling in innate immunity and inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 3, 2012.

[35] B. Raupe, S. K. Peuschel, D. M. Monack, and A. Zychlinski, “Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection,” Infection and Immunity, vol. 74, no. 8, pp. 4922–4926, 2006.

[36] A. Sarkar, M. W. Hall, M. Exline et al., “Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1ß and interleukin-18,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 9, pp. 1003–1010, 2006.

[37] B. W. van Tassell, J. M. Raleigh, and A. Abbate, “Targeting interleukin-1 in heart failure and inflammatory heart disease,” Current Heart Failure Reports, vol. 12, no. 1, pp. 33–41, 2015.

[38] B. W. van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate, “Targeting interleukin-1 in heart disease,” Circulation, vol. 128, no. 17, pp. 1910–1923, 2013.

[39] B. J. M. H. Jefferis, O. Papacosta, C. G. Owen et al., “Interleukin 18 and coronary heart disease: prospective study and systematic review,” Atherosclerosis, vol. 217, no. 1, pp. 227–233, 2011.

[40] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.

[41] H. Dweep, C. Sticht, P. Pandey, and N. Gretz, “miRWalk—database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes,” Journal of Biomedical Informatics, vol. 44, no. 5, pp. 839–847, 2011.

[42] F. Bauernfeind, A. Rieger, F. A. Schildberg, P. A. Knolle, J. L. Schmid-Burgk, and V. Hornung, “NLRP3 inflammasome activity is negatively controlled by miR-223,” Journal of Immunology, vol. 189, no. 8, pp. 4175–4181, 2012.

[43] M. Haneklaus, M. Gerlic, M. Kurowska-Stolarska et al., “Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1ß production,” Journal of Immunology, vol. 189, no. 8, pp. 3795–3799, 2012.

[44] S. Greco, P. Fasanaro, S. Castelvecchio et al., “MicroRNA dysregulation in diabetic ischemic heart failure patients,” Diabetes, vol. 61, no. 6, pp. 1633–1641, 2012.

[45] S. Ikeda, S. W. Kong, J. Lu et al., “Altered microRNA expression in human heart disease,” Physiological Genomics, vol. 31, no. 3, pp. 367–373, 2007.

[46] Y. Kuwabara, K. Ono, T. Horie et al., “Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage,” Circulation: Cardiovascular Genetics, vol. 4, no. 4, pp. 446–454, 2011.

[47] A. Caré, D. Catalucci, F. Felicetti et al., “MicroRNA-133 controls cardiac hypertrophy,” Nature Medicine, vol. 13, no. 5, pp. 613–618, 2007.

[48] E. Mezzaroma, S. Toldo, D. Farkas et al., “The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 49, pp. 19725–19730, 2011.

[49] S. Chen and B. Sun, “Negative regulation of NLRP3 inflammasome signaling,” Protein & Cell, vol. 4, no. 4, pp. 251–258, 2013.

[50] N. Mizushima and M. Komatsu, “Autophagy: renovation of cells and tissues,” Cell, vol. 147, no. 4, pp. 728–741, 2011.

[51] K. Cadwell, J. Y. Liu, S. L. Brown et al., “A key role for autophagy and the autophagy gene Atg6Sl in mouse and human intestinal Paneth cells,” Nature, vol. 456, no. 7219, pp. 259–263, 2008.

[52] T. Saitoh, N. Fujita, M. H. Jang et al., “Loss of the autophagy protein Atg6Sl enhances endotoxin-induced IL-1ß production,” Nature, vol. 456, no. 7219, pp. 264–268, 2008.

[53] E.-L. Eskelinen and P. Saftig, “Autophagy: a lysosomal degradation pathway with a central role in health and disease,” Biochimica et Biophysica Acta, vol. 1793, no. 4, pp. 664–673, 2009.

[54] K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., “Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome,” Nature Immunology, vol. 12, no. 3, pp. 222–230, 2011.

[55] C. D. Krause, W. He, S. Kotenko, and S. Pestka, “Modulation of the activation of Stat1 by the interferon-gamma receptor complex,” Cell Research, vol. 16, no. 1, pp. 113–123, 2006.

[56] G. Guarda, M. Braun, F. Staehli et al., “Type I interferon inhibits interleukin-1 production and inflammasome activation,” Immunity, vol. 34, no. 2, pp. 213–223, 2011.

[57] X. Li, N. Du, Q. Zhang et al., “MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy,” Cell Death and Disease, vol. 5, no. 10, Article ID e1479, 2014.

[58] D. Lu, J. Liu, J. Jiao et al., “Transcription factor Foxo3a prevents apoptosis by regulating calcium through the apoptosis repressor with caspase recruitment domain,” Journal of Biological Chemistry, vol. 288, no. 12, pp. 8491–8504, 2013.

[59] J. Wang, W. Huang, R. Xu et al., “MicroRNA-24 regulates cardiac fibrosis after myocardial infarction,” Journal of Cellular and Molecular Medicine, vol. 16, no. 9, pp. 2150–2160, 2012.

[60] J. Fiedler, V. Jazbutyte, B. C. Kirchmaier et al., “MicroRNA-24 regulates vascularity after myocardial infarction,” Circulation, vol. 124, no. 6, pp. 720–730, 2011.

[61] S. Dong, Y. Cheng, J. Yang et al., “MicroRNA expression signature and the role of MicroRNA-21 in the early phase of acute myocardial infarction,” The Journal of Biological Chemistry, vol. 284, no. 43, pp. 29514–29525, 2009.
[62] N. Zidar, E. Boštjančič, D. Glavač, and D. Štajer, “MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction,” *Disease Markers*, vol. 31, no. 5, pp. 259–265, 2011.

[63] H. Y. Seok, J. Chen, M. Kataoka et al., “Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy,” *Circulation Research*, vol. 114, no. 10, pp. 1585–1595, 2014.

[64] S. V. Naga Prasad, Z.-H. Duan, M. K. Gupta et al., “Unique MicroRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks,” *The Journal of Biological Chemistry*, vol. 284, no. 40, pp. 27487–27499, 2009.

[65] D. Sayed, C. Hong, I.-Y. Chen, J. Lypowy, and M. Abdellatif, “MicroRNAs play an essential role in the development of cardiac hypertrophy,” *Circulation Research*, vol. 100, no. 3, pp. 416–424, 2007.

[66] E. van Rooij, L. B. Sutherland, N. Liu et al., “A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 48, pp. 18255–18260, 2006.

[67] K. Mao, S. Chen, M. Chen et al., “Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock,” *Cell Research*, vol. 23, no. 2, pp. 201–212, 2013.

[68] R. Zamora, Y. Vodovoz, and T. R. Billiar, “Inducible nitric oxide synthase and inflammatory diseases,” *Molecular Medicine*, vol. 6, no. 5, pp. 347–373, 2000.

[69] E. Hernandez-Cuellar, K. Tsuchiya, H. Hara et al., “Cutting edge: nitric oxide inhibits the NLRP3 inflammasome,” *The Journal of Immunology*, vol. 189, no. 11, pp. 5113–5117, 2012.